Take heed to this text
EndoQuest Robotics Inc. and Omnivision have partnered to combine Omnivision’s CameraCubeChip into EndoQuest’s surgical robotic system.
Santa Clara, Calif.-based Omnivision develops semiconductor techniques, together with superior digital imaging and contact show know-how.
Houston-based EndoQuest designed its system to handle unmet wants in gastrointestinal and different endoluminal surgical procedures. The firm mentioned its proprietary know-how navigates throughout the physique’s lumina areas such because the gut. This supplies the precision and adaptability for minimally invasive interventions, which might enhance affected person outcomes, it mentioned.
EndoQuest added that its platform permits therapeutic endoscopists and surgeons to function by means of a trans-oral or trans-anal method. Final month, the corporate raised $42 million. Final week, the U.S. Meals and Drug Administration’s Safer Applied sciences Program (STeP) accepted the surgical robotic system.
Omnivision to allow clearer surgical visualization
Omnivision designed the CameraCubeChip visualization system with its PureCel Plus-S pixel know-how.
PureCel Plus-S allows “excessive full-well capability, zero blooming and decrease energy consumption with crisp, clear, life-like photos,” mentioned Tehzeeb Gunja, director of medical advertising at Omnivision. He added that the compact, medical-grade providing may take affected person care and surgical visualization “to the subsequent degree.”
“We’re excited to have the ability to incorporate Omnivision’s market-leading sensor know-how into the visualization element of our first-of-its-kind platform,” mentioned Kurt Azarbarzin, CEO of EndoQuest Robotics, in a launch. “We acknowledge that superior imaging is crucial to enhancing doctor capabilities, particularly contained in the lumen of the gastrointestinal (GI) tract. Omnivision’s latest know-how is good for our versatile robotic system.”
EndoQuest expects STeP to speed up entry
STeP supplies a streamlined growth and market assessment course of for eligible medical gadgets with the aim of accelerating affected person entry with out compromising security and efficacy. The FDA launched STeP in 2021, modeling this system on its breakthrough gadgets designation program.
STeP covers gadgets that might enhance the security of remedies or diagnostics. They have to be designed to deal with underlying illnesses or situations thought of much less severe than these handled or recognized by gadgets eligible for breakthrough designation.
“We imagine that our distinctive robotic platform will improve doctor management, precision, and effectivity, enabling safer and simpler minimally invasive remedies,” acknowledged Azarbarzin. “We sit up for working with the FDA to convey the Versatile Robotic System to market and supply physicians and sufferers a brand new, scar-free method for all kinds of medical situations and procedures.”
Editor’s observe: This text was syndicated from MassDevice, a sibling web site to The Robotic Report.